In focus · trending topic

T-cell Lymphoma

2 stories · following the connections

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)

By Nasdaq OMXApr 13, 2018, 11:00 AM UTC

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA

By Nasdaq OMXDec 5, 2017, 12:00 PM UTC